Avicanna Inc. (TSX: AVCN)
Health Care · Pharmaceuticals · CA
CA$0.12
+15.00% today · -57.4% 1Y
Avicanna Inc. (TSX: AVCN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.10M and employs 112 people.
Over the last twelve months the share price has lost 57.4%, trading between 0.10 and 0.30.
Tweenvest scores Avicanna Inc. across four factors: quality 51/100, value 71/100, growth 100/100. Its strongest factor is growth.
AVCN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.10M
- Revenue (TTM)
- $17.83M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- CA$0.30
- 52-week low
- CA$0.10
- Avg volume (3M)
- —
- Shares outstanding
- 137.72M
- Employees
- 112
- Next earnings
- —
About Avicanna Inc.
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
- ISIN
- CA05368K1003
- Founded
- 2016
- Listed since
- Jul 18, 2019
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Silva Pharmaceuticals LimitedDSE: SILVAPHL | $11.53M | Tk10.40 | -16.80% |
| IDT Australia LimitedASX: IDT | $11.33M | AU$0.04 | -7.32% |
| Together Pharma LtdTASE: TGTR | $11.32M | ₪2.00 | -3.71% |
| Pharmaids Pharmaceuticals LimitedBSE: 524572 | $11.23M | Rs30.81 | +2.19% |
| Makers Laboratories LimitedBSE: 506919 | $11.07M | Rs181.60 | -0.06% |
| Tyche Industries LimitedBSE: 532384 | $11.03M | Rs104.20 | -0.71% |
| Ben Tre Pharmaceutical Joint Stock CompanyHOSE: DBT | $11.03M | ₫13,000.00 | -1.52% |
| DIOD Maker of Eco-Friendly Equipment and Nutrition Public Joint Stock CompanyMISX: DIOD | $10.74M | RUB— | — |
Figures last refreshed Oct 11, 2026.